A dose-finding study of zoledronate in hypercalcemic cancer patients

Journal of Bone and Mineral Research

Volumn 14, Issue 9, 1999, Pages 1557-1561

  Body, J J ^a   Lortholary, A ^b   Romieu, G ^c   Vigneron, A M ^d   Ford, J ^d  

^a JULES BORDET INSTITUTE   (Belgium)

^b CENTRE PAUL PAPIN   (France)

^c CENTRE VAL D AURELLE   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

EID: 0032880063     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.9.1557     Document Type: Article

References (13)

1. Fleisch H 1997 Bisphosphonates in Bone Disease - From the Laboratory to the Patient, 3rd Ed. The Parthenon Publishing Group, London, U.K.
2. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Heisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AHG, Rubens RD, for the International Bone and Cancer Study Group 1998 Current use of bisphosphonates in oncology. J Clin Oncol 16:3890-3899.
3. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ, for the Protocol 19 Aredia Breast Cancer Study Group 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044.
4. Berenson JR, Lichtenstein A, Porter L, Dimopoulous A, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD, for the Myeloma Aredia Study Group 1998 Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16:593-602.
5. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA 1998 A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Hematol 100:317-325.
6. Green JR, Müller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-750.
7. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ 1997 Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 75:295-300.
8. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE 1995 A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72:1289-1293.
9. Body JJ, Dumon JC 1994 Treatment of tumor-induced hyper-calcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 5:359-363.
10. Berenson JR, Lipton A, Rosen LS, et al. 1996 Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood 88 (Suppl 1):586a.
11. Body JJ 1997 Clinical research update: Zoledronate. Cancer 80:1699-1701.
12. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S 1993 Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65.
13. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Basiert G 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363.